Oral erythromycin in pityriasis lichenoides chronica and pityriasis lichenoides et varioliformis acuta.
erythromycin
pityriasis lichenoides chronica (PLC)
pityriasis lichenoides et varioliformis acuta (PLEVA)
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
11
03
2020
accepted:
12
03
2020
pubmed:
17
3
2020
medline:
15
5
2021
entrez:
17
3
2020
Statut:
ppublish
Résumé
Pityriasis lichenoides (PL) is an uncommon cutaneous disorder. Oral erythromycin is proposed to be effective in treating the disease. Here, we reported 16 pediatric patients with PL and systematically reviewed published literatures on erythromycin treatment response in pediatric PL patients, to observe the different treatment response to erythromycin in the pityriasis lichenoides chronica (PLC) and the pityriasis lichenoides et varioliformis acuta (PLEVA) groups. Sixteen patients, 8 with PLC and 8 with PLEVA, were treated with erythromycin. In the PLC group, 25% (n = 2) patients responded to erythromycin, while in the PLEVA group, 87.5% (n = 7) patients responded to erythromycin. The response rate was higher in the PLEVA group than the PLC group (P =.05). No side effect was reported in the 16 patients. A total of 34 children including 16 from our studies were included for further descriptive analysis, in which 12 had PLC and 22 had PLEVA. In the PLC group, 41.7% (n = 5) of patients responded to erythromycin while in the PLEVA group, 90.9 % (n = 20) of patients responded. The response rate was higher in the PLEVA group than the PLC group (P = .004). In conclusion, erythromycin is effective and safe in the treatment of children with PL, and erythromycin was more effective in patients with PLEVA than PLC.
Substances chimiques
Erythromycin
63937KV33D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13311Subventions
Organisme : Capital Clinical Characteristics of China
ID : Z161100000516070
Pays : International
Organisme : National Natural Science Foundation of China
ID : 81673042
Pays : International
Organisme : Natural Science Foundation of Beijing Municipality
ID : 7174300
Pays : International
Organisme : The Pediatric Medical Coordinated Development Center of Beijing Municipal Administration
ID : XTZD20180502
Pays : International
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Geller L, Antonov NK, Lauren CT, Morel KD, Garzon MC. Pityriasis lichenoides in childhood: review of clinical presentation and treatment options. Pediatr Dermatol. 2015;32:579-592.
Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol. 2007;8:29-36.
Cuellar-Barboza A, Cardenas-De La Garza JA, Villarreal-Villarreal CD, et al. Efficacy of phototherapy in pityriasis lichenoides chronica of dark skin: a retrospective study from a tertiary center in Mexico. Dermatol Ther. 2018;31:e12734.
Ersoy-Evans S, Greco MF, Mancini AJ, Subasi N, Paller AS. Pityriasis lichenoides in childhood: a retrospective review of 124 patients. J Am Acad Dermatol. 2007;56:205-210.
Gelmetti C, Rigoni C, Alessi E, Ermacora E, Berti E, Caputo R. Pityriasis lichenoides in children: a long-term follow-up of eighty-nine cases. J Am Acad Dermatol. 1990;23:473-478.
Hapa A, Ersoy-Evans S, Karaduman A. Childhood pityriasis lichenoides and oral erythromycin. Pediatr Dermatol. 2012;29:719-724.
Koh WL, Koh MJ, Tay YK. Pityriasis lichenoides in an Asian population. Int J Dermatol. 2013;52:1495-1499.
Romani J, Puig L, Fernandez-Figueras MT, de Moragas JM. Pityriasis lichenoides in children: clinicopathologic review of 22 patients. Pediatr Dermatol. 1998;15:1-6.
Shavin JS, Jones TM, Aton JK, Abele DC, Smith JG Jr. Mucha-Habermann's disease in children: treatment with erythromycin. Arch Dermatol. 1978;114:1679-1680.
Truhan AP, Hebert AA, Esterly NB. Pityriasis lichenoides in children: therapeutic response to erythromycin. J Am Acad Dermatol. 1986;15:66-70.
Van TN, Thi TN, Huu DL, et al. Clinical aspects and treatment of pityriasis lichenoides et varioliformis acuta: a retrospective Vietnamese study. Open Access Maced J Med Sci. 2019;7:198-199.
Wahie S, Hiscutt E, Natarajan S, Taylor A. Pityriasis lichenoides: the differences between children and adults. Br J Dermatol. 2007;157:941-945.
Farnaghi F, Seirafi H, Ehsani AH, Agdari ME, Noormohammadpour P. Comparison of the therapeutic effects of narrow band UVB vs. PUVA in patients with pityriasis lichenoides. J Eur Acad Dermatol Venereol. 2011;25:913-916.
Jung F, Sibbald C, Bohdanowicz M, Ingram JR, Piguet V. Systematic review of efficacies and adverse effects of treatments for pityriasis lichenoides. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.18977
Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. 2001;121:83-92.
Boivin MA, Carey MC, Levy H. Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects. Pharmacotherapy. 2003;23:5-8.